Stock Expert AI
IMNN company logo

IMNN: AI 评分 46/100 — AI 分析 (4月 2026)

Imunon, Inc. is a clinical-stage biotechnology company focused on developing DNA-based immunotherapies and vaccines. Their lead product, GEN-1, targets localized treatment of ovarian cancer.

Key Facts: Price: $3.80 AI Score: 46/100 Sector: Healthcare

公司概况

概要：

Imunon, Inc. is a clinical-stage biotechnology company focused on developing DNA-based immunotherapies and vaccines. Their lead product, GEN-1, targets localized treatment of ovarian cancer.
Imunon, Inc. pioneers DNA-based immunotherapies, offering innovative cancer treatments like GEN-1 for ovarian cancer, and ThermoDox for various cancer indications, positioning them at the forefront of personalized medicine with feasibility stage platform technologies and a market cap of $0.01 billion.

IMNN是做什么的？

Imunon, Inc., founded in 1982 and formerly known as Celsion Corporation until September 2022, is a clinical-stage biotechnology company headquartered in Lawrenceville, New Jersey. The company is dedicated to the development and commercialization of innovative DNA-based immunotherapies, vaccines, and directed chemotherapies for the treatment of cancer. Imunon's lead product candidate, GEN-1, is a DNA-based immunotherapy designed for the localized treatment of ovarian cancer. This novel approach aims to stimulate the patient's immune system to target and destroy cancer cells within the peritoneal cavity. Another key asset in Imunon's pipeline is ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, a well-established chemotherapy drug. ThermoDox is being developed for various cancer indications, leveraging its ability to deliver a concentrated dose of chemotherapy directly to the tumor site when activated by heat. In addition to these clinical-stage programs, Imunon has two feasibility stage platform technologies focused on the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. These platforms represent the company's commitment to innovation and its vision for the future of cancer treatment. With a team of 25 employees, Imunon is focused on advancing its pipeline and forging strategic partnerships to bring its novel therapies to patients in need.

IMNN的投资论点是什么？

Investing in Imunon, Inc. (IMNN) presents a compelling opportunity due to its innovative DNA-based immunotherapy platform and promising clinical pipeline. The lead product, GEN-1, targeting localized ovarian cancer, has the potential to address a significant unmet medical need. Positive clinical trial data and strategic partnerships could drive significant value appreciation. The company's ThermoDox program, utilizing heat-activated liposomal doxorubicin, offers another avenue for growth across various cancer indications. With a market capitalization of $0.01 billion and a beta of 2.06, IMNN offers high-risk, high-reward potential. Upcoming clinical trial results for GEN-1 and ThermoDox represent key catalysts that could significantly impact the stock's performance.

IMNN在哪个行业运营？

Imunon operates within the biotechnology industry, a sector characterized by intense research and development, high regulatory hurdles, and significant growth potential. The market for cancer therapies is substantial and growing, driven by an aging population and increasing cancer incidence rates. Imunon's focus on DNA-based immunotherapies aligns with the broader industry trend towards personalized medicine and targeted therapies. Competitors include companies like AEON, BOLT, CING, CLRB, and COCP, each pursuing different approaches to cancer treatment. The success of Imunon will depend on its ability to differentiate its technologies, navigate the regulatory landscape, and secure funding to advance its clinical programs.
Biotechnology
Healthcare

IMNN有哪些增长机遇？

  • GEN-1 Clinical Advancement: The continued clinical development of GEN-1 for localized treatment of ovarian cancer represents a significant growth opportunity. Positive Phase 2/3 trial results could lead to accelerated regulatory approval and commercialization. The ovarian cancer market is estimated to reach $4.5 billion by 2028, providing a substantial addressable market for GEN-1.
  • ThermoDox Expansion: Expanding the clinical development of ThermoDox to additional cancer indications beyond the current focus represents another key growth driver. The global market for liposomal doxorubicin is projected to reach $1.2 billion by 2027. Successful clinical trials in indications such as liver cancer or sarcoma could unlock significant value.
  • Platform Technology Development: Leveraging the company's two feasibility stage platform technologies to develop new nucleic acid-based immunotherapies and vaccines offers long-term growth potential. These platforms could generate a pipeline of novel product candidates targeting a wide range of diseases.
  • Strategic Partnerships: Forming strategic partnerships with larger pharmaceutical companies or biotechnology firms could provide access to funding, expertise, and commercialization capabilities. Collaborations could accelerate the development and launch of Imunon's products and expand its market reach.
  • Regulatory Approvals and Market Access: Securing regulatory approvals for GEN-1 and ThermoDox in key markets, such as the United States and Europe, is critical for commercial success. Successful navigation of the regulatory landscape and securing favorable reimbursement policies will be essential for maximizing market penetration.
  • Market capitalization of $0.01 billion indicates micro-cap status with potential for high growth.
  • P/E ratio of -0.68 reflects the company's current lack of profitability, common for clinical-stage biotech companies.
  • Beta of 2.06 suggests higher volatility compared to the overall market.
  • Focus on DNA-based immunotherapies positions the company in a rapidly evolving field of cancer treatment.
  • GEN-1 and ThermoDox represent key assets with potential to address unmet needs in ovarian cancer and other cancer indications.

IMNN提供哪些产品和服务？

  • Develops DNA-based immunotherapies for cancer treatment.
  • Creates vaccines for various diseases.
  • Works on directed chemotherapies to target cancer cells.
  • Focuses on localized treatment of ovarian cancer with GEN-1.
  • Utilizes heat-activated liposomal encapsulation of doxorubicin with ThermoDox.
  • Develops nucleic acid-based immunotherapies and vaccines.

IMNN如何赚钱？

  • Develops and patents novel cancer therapies.
  • Conducts clinical trials to demonstrate safety and efficacy.
  • Seeks regulatory approval from agencies like the FDA.
  • Commercializes approved therapies through partnerships or direct sales.
  • Patients with cancer, particularly ovarian cancer.
  • Hospitals and oncology clinics.
  • Pharmaceutical companies (potential partners).
  • Research institutions.
  • Proprietary DNA-based immunotherapy technology.
  • Patents protecting GEN-1 and ThermoDox.
  • Clinical data supporting the efficacy of its products.
  • Expertise in developing and commercializing cancer therapies.

什么因素可能推动IMNN股价上涨？

  • Upcoming: GEN-1 Phase 2/3 clinical trial results for ovarian cancer.
  • Upcoming: ThermoDox clinical trial updates in various cancer indications.
  • Ongoing: Potential for strategic partnerships and collaborations.
  • Ongoing: Advancements in platform technology development.

IMNN的主要风险是什么？

  • Potential: Clinical trial failures for GEN-1 or ThermoDox.
  • Potential: Regulatory delays or rejections.
  • Ongoing: Competition from larger biotechnology and pharmaceutical companies.
  • Ongoing: Need for additional funding and potential dilution of existing shareholders.
  • Ongoing: Dependence on key personnel.

IMNN的核心优势是什么？

  • Innovative DNA-based immunotherapy platform.
  • Promising clinical pipeline with GEN-1 and ThermoDox.
  • Experienced management team.
  • Proprietary technology and patents.

IMNN的劣势是什么？

  • Limited financial resources.
  • Dependence on clinical trial success.
  • High regulatory hurdles.
  • Lack of commercialized products.

IMNN有哪些机遇？

  • Strategic partnerships with larger pharmaceutical companies.
  • Expansion of ThermoDox to additional cancer indications.
  • Development of new therapies using platform technologies.
  • Positive clinical trial results leading to regulatory approvals.

IMNN面临哪些威胁？

  • Competition from other biotechnology companies.
  • Clinical trial failures.
  • Regulatory setbacks.
  • Dilution of existing shareholders through fundraising.

IMNN的竞争对手是谁？

  • Aeon Biopharma, Inc. — Focuses on botulinum toxin therapies. — (AEON)
  • Bolt Biotherapeutics, Inc. — Develops immune-stimulating antibody conjugates. — (BOLT)
  • Cingulate Inc. — Develops therapies for ADHD and other cognitive disorders. — (CING)
  • Cellectar Biosciences Inc. — Develops phospholipid drug conjugates for cancer. — (CLRB)
  • Cocrystal Pharma, Inc. — Develops antiviral therapeutics. — (COCP)

Key Metrics

  • Price: $3.80 (+6.74%)
  • Market Cap: $10.0M
  • MoonshotScore: 46/100

常见问题

What does Imunon, Inc. (IMNN) do?

Imunon, Inc. (IMNN) is a clinical-stage biotechnology company focused on developing and commercializing DNA-based immunotherapies, vaccines, and directed chemotherapies for cancer treatment. Their lead product, GEN-1, is a DNA-based immunotherapy for localized treatment of ovarian cancer, aiming to stimulate the patient's immune system to target and destroy cancer cells. Additionally, they are developing ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, for various cancer indications, showcasing their commitment to innovative cancer therapies.

Is IMNN stock a good buy?

Evaluating whether IMNN stock is a good buy requires careful consideration of its high-risk, high-reward profile. With a market cap of $0.01 billion and a negative P/E ratio, IMNN is a micro-cap company with significant growth potential but also substantial risk. Positive clinical trial results for GEN-1 or ThermoDox could drive significant stock appreciation. However, potential clinical trial failures and the need for additional funding pose significant risks. Investors should weigh their risk tolerance and conduct thorough due diligence before investing.

What are the risks of investing in IMNN?

Investing in Imunon (IMNN) carries several risks inherent to clinical-stage biotechnology companies. A primary risk is the potential for clinical trial failures, which could significantly impact the company's valuation and future prospects. The company also faces regulatory risks associated with obtaining approvals for its therapies. Furthermore, IMNN requires additional funding to advance its clinical programs, potentially leading to dilution of existing shareholders. Competition from larger, more established biotechnology companies also poses a threat to IMNN's market position.

What catalysts could move IMNN stock?

Several catalysts could potentially move IMNN stock. Positive clinical trial results for GEN-1 in ovarian cancer or ThermoDox in other cancer indications would likely drive significant stock appreciation. The announcement of strategic partnerships with larger pharmaceutical companies could also boost investor confidence and increase the stock price. Furthermore, any advancements in the company's platform technology development or positive regulatory updates could serve as catalysts for IMNN stock.

What is IMNN stock price target?

As of March 3, 2026, there is no readily available analyst consensus price target for IMNN stock due to its micro-cap status and limited analyst coverage. Determining a fair value estimate would require a detailed analysis of the company's pipeline, clinical trial data, and financial projections. Investors should conduct their own due diligence and consider the inherent risks and uncertainties associated with investing in a clinical-stage biotechnology company before making any investment decisions.

热门股票

查看全部股票 →